MR Antagonist and LSD1

• Status: Not yet recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Amlodipine; Eplerenone

Criteria

Inclusion Criteria:

• untreated as well as currently treated hypertensives

• rs587168 allele carriers

• not on more than two anti-hypertensives

• normal renal, metabolic, electrolyte, and CBC laboratory tests

• self-identified Black race

• age >17 yrs.

Exclusion Criteria:

• known cardiac disease other than HTN

• renal, circulatory or neurologic diseases

• diabetes

• smoking

• secondary HTN as indicated by history, physical examination or screening blood and urine tests

• smoking

• any drug therapy, except for anti-hypertensives and stable thyroid medication replacement